Societe Generale set a CHF 95 price objective on Novartis (VTX:NOVN) in a research note published on Wednesday, March 14th. The brokerage currently has a buy rating on the stock.
A number of other analysts also recently issued reports on the company. Bank of America set a CHF 87 price objective on Novartis and gave the stock a sell rating in a research note on Wednesday, December 6th. JPMorgan Chase set a CHF 84 price objective on Novartis and gave the stock a neutral rating in a research note on Friday, December 29th. Morgan Stanley set a CHF 92 target price on Novartis and gave the stock a buy rating in a report on Friday, December 1st. Barclays set a CHF 80 target price on Novartis and gave the stock a sell rating in a report on Tuesday, February 20th. Finally, Baader Bank set a CHF 95 target price on Novartis and gave the stock a buy rating in a report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. Novartis has an average rating of Hold and a consensus price target of CHF 88.89.
VTX:NOVN traded up CHF 0.34 during trading hours on Wednesday, reaching CHF 78.38. The stock had a trading volume of 11,210,000 shares, compared to its average volume of 5,980,000. Novartis has a 52 week low of CHF 72.45 and a 52 week high of CHF 88.30.
TRADEMARK VIOLATION WARNING: “Novartis (NOVN) Given a CHF 95 Price Target by Societe Generale Analysts” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/novartis-novn-pt-set-at-chf-95-by-societe-generale-2.html.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.